<DOC>
	<DOCNO>NCT01362153</DOCNO>
	<brief_summary>This Phase 1 , pharmacokinetic pharmacodynamic study intravenous subcutaneous administer golimumab patient rheumatoid arthritis .</brief_summary>
	<brief_title>A Pharmacokinetic ( PK ) Pharmacodynamic ( PD ) Study Golimumab Patients With Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description>A Phase 1 , randomize ( study drug route administration assign chance ) , open label ( physician patient know golimumab assign ) , study golimumab patient rheumatoid arthritis ( RA ) . The purpose study compare pharmacokinetic ( body effect drug ) pharmacodynamic ( drug effect body ) effect golimumab administer vein arm injection skin . Safety assessment perform throughout study include obtain evaluate laboratory test , vital sign ( eg , blood pressure ) , occurrence severity adverse event . The study also assess clinical effect golimumab RA . The study plan approximately 45 patient , randomize 2:1 ratio receive golimumab SC IV . Male female patient diagnose RA least 3 month 18 year age old may able participate . Subcutaneous ( SC ) injections 100 mg golimumab every 4 week Week 20 intravenous ( IV ) administrations 2 mg/kg golimumab Days 1 85 .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Have diagnosis RA least 3 month prior screen Have history latent active tuberculosis ( TB ) test negative TB Have inflammatory disease RA Have treat diseasemodifying antirheumatic drug ( DMARDs ) /systemic immunosuppressive methotrexate ( MTX ) , sulfasalazine , hydroxychloroquine 4 week prior first administration study agent Have receive intramuscular ( IM ) , IV , intraarticular corticosteroid within 4 week study agent administration Have know hypersensitivity human Ig protein Have receive infliximab , golimumab , adalimumab abatacept within 3 month , etanercept anakinra within 1 month prior first administration study agent Have receive alefacept , efalizumab , natalizumab , rituximab , Bcelldepleting agent Have treat biologics investigational drug , within 5 halflives drug prior first administration study agent Have history latent active granulomatous infection , include tuberculosis ( TB ) , histoplasmosis , coccidioidomycosis , prior screen Have Bacille CalmetteGuerin ( BCG ) vaccination within 12 month screen Have serious infection ( eg , hepatitis , pneumonia , pyelonephritis , sepsis )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Golimumab</keyword>
	<keyword>Simponi</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>PK</keyword>
	<keyword>PD</keyword>
</DOC>